Compare GSK plc (GSK) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Oxford Lane Capital Corp — how do they compare? GSK plc trades at $52.53 (market cap $101.34B), while Oxford Lane Capital Corp trades at $9.02 (market cap $881.29M). The key difference: GSK plc is far larger — about 115× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (26.59%). Which is the better fit depends on your goals.
| GSK | OXLC | |
|---|---|---|
Market Cap | $101.34B | $881.29M |
Sector | Health | Financials |
52-Week High | $61.18 | $20.75 |
52-Week Low | $36.20 | $8.15 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | 26.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
OXLC trades at $9.035, down 1.04% with a bearish technical signal. The company reported negative earnings surprises in recent quarters, including a significant Q1 2026 miss, while maintaining a high dividend yield. Analyst sentiment is mixed with a 50% buy rating, but negative ROE and ROA raise concerns about financial health.
The outlook remains challenging with declining net asset value and operational cash flow deficits. While the high dividend yield attracts income investors, sustainability concerns persist given the negative profitability metrics and recent earnings underperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
